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a b s t r a c t
The development of new generation vaccines is an imperative tool to counteract accidental or intended
release of bio-threat agents, such as Bacillus anthracis, Yersinia pestis and variola virus, and to control
natural outbreaks. In the past few years, numerous data accumulated on the immunogenicity and safety
of plant-made vaccines against bio-security-related organisms. In addition, expression levels achieved
for these antigenic proteins are practical for the production of sufficient material for large-scale vacci-
nation programs. These data demonstrated that the plant-based approach is feasible for manufacturing
recombinant vaccines against bio-terror agents that could be mass-produced at reasonable cost.
© 2009 Elsevier Ltd. All rights reserved.
1. Introduction
Bioterrorism is defined as the deliberate use of microorganisms
or toxins derived from living organisms to cause death or disease
in humans and animals [1]. The ∼200 pathogens reported to be
potential agents for bioterrorism are classified into three differ-
ent categories according to the infectiousness, virulence, severity of
impact on human health, and cost [1]. The Centers for Disease Con-
trol (CDC) lists as “Category A biological agents” pathogens such as
Bacillus anthracis, Yersinia pestis and variola virus. The most effec-
tive way to prevent the use of biological agents as a weapon would
be to produce efficacious vaccines; however, traditional vaccines
are inappropriate for rapid widespread administration following
a terrorist attack. Transgenic plants that express recombinant pro-
teins are economical and convenient vehicles to produce protective
antigens (PAs). Plant-derived subunit vaccines lack contamination
with animal pathogens, are heat stable and may be engineered to
contain multiple antigens. In addition, transgenic plants have low
rawmaterial cost and enable rapid scale-up capacity. Selected plant
tissues are also suitable for oral administration, thus reducing pain
and discomfort, eliminating needle-associated risks, and inducing
mucosal immunity. We present an overview of expression of tar-
get antigens produced in plants for the development of vaccines
against bio-threat agents, such as B. anthracis, Y. pestis and variola
virus.
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2. Approaches to produce vaccines in plants
Several approaches have been used to produce subunit vaccines,
including those against bio-threat agents, in plants (Table 1). To
date, themajority of plant-derived pharmaceuticals have been pro-
duced by nuclear transformation, wherein the gene of interest is
incorporated into theplantnuclear genome.However, randominte-
gration of foreign gene via non-homologous recombination results
in transformed lines with high variability of transgene expression.
In addition, expressed sequences canbe subjected to gene silencing,
and the foreign proteins are often rapidly degraded in plant tissues
[2]. The average protein accumulation levels achieved (0.01–0.4%
TSP) are too low for cost-effective production of molecules that can
generate a protective immune response, and induce tolerance in
individuals [3]. Nevertheless, nuclear transformation remains the
most versatile technology, as many species are amenable to trans-
formation and it is possible to specify in which tissue the protein
should accumulate [4]. Moreover, the recombinant protein can be
targeted to a specific subcellular organelle or compartment, thus
increasing expression and allowing post-translational modifica-
tions, such as glycosylation [5,6].
A promising alternative for plant-based expression of biophar-
maceuticals is to integrate target genes into the plastid genome.
Once stably integrated, transgenes express large amounts of pro-
teins due to the high copy number of the chloroplast genome in
each plant cell [7]. Chloroplast transformation offers several advan-
tage over nuclear transformation, including uniform transgene
expression rates, no gene silencing and gene/product contain-
ment. On the other hand, only few species are amenable to plastid
transformation and plastid expression offers fewer alternatives
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Table 1
Examples of bio-security-related antigen production by different plant-based technologies.
Target Antigen Technology Expression level Reference
Bacillus anthracis PA Chloroplast transformation (tobacco) 14.2% TSPa [14]
B. anthracis PAD4, LFD1 Transient expression (Nicotiana benthamiana) N.D. [15]
B. anthracis CTB-LF Nuclear transformation (potato) 0.002% TSPa [12]
B. anthracis PA Nuclear transformation (tomato) N.D. [3]
Yersinia pestis F1, V, F1–V Transient expression (N. benthamiana) 2mg/g FWb [17]
Y. pestis F1–V Transient expression (N. benthamiana) N.D. [18]
Y. pestis F1–V Nuclear transformation (tomato) 4% TSPa [16]
Y. pestis F1–V Chloroplast transformation (tobacco) 14.8% TSPa [7]
Variola virus B5c Transient expression (N. benthamiana) 100mg/kg (freeze-dried material) [22]
Variola virus A27Lc Nuclear and chloroplast transformation (tobacco) 0.04% (nuclear) and 18% (chloroplast) TSPa Rigano et al. (unpublished) [20]
a TSP, total soluble protein.
b FW, fresh weight.
c From vaccinia virus.
for post-translational modifications. However, recent studies have
shown that protein oligomerization, disulphide-bond formation
and lipidation can occur also in the chloroplast [2,8,9].
Analternative approach forproducing largequantities of vaccine
antigens is to transiently express proteins from recombinant plant
viral sequences inoculated onto plants. This technique provides an
ideal strategy to produce recombinant molecules in a short period
of time. Typically, recombinant proteins have been expressed using
plant viral RNA vectors. Recently, hybrid vectors that combine ele-
ments of plant RNAviral vectors andAgrobacteriumbinaryplasmids
were developed to enable uniformly high levels of target protein
expression and rapid scaleup [10].
3. Plant-based vaccines against bio-security-related
organisms
3.1. Anthrax
B. anthracis is the causative agent of anthrax. Anthrax is consid-
ered to be one of the most potent bio-terror agents, as B. anthracis
spores can be transmitted by aerosolization. Anthrax inhalation
has a high mortality rate, and the organism’s spores are quite sta-
ble in the environment [1]. Vaccination against anthrax has been
considered the most effective prophylactic measure. However, the
current licensed anthrax vaccine is a cell-free preparation derived
from an attenuated B. anthracis strain in which production process
is complicated and imprecise. Moreover, the vaccine requires an
extended immunization program and has a relatively high inci-
dence of side effects [4]. New generation subunit vaccines against
anthrax have targeted the components of the multicomponent
lethal toxin, which consist of the PA and lethal factor (LF). The
first reports of PA expression in plants were based on nuclear-
transgenic tobacco, potato and tomato plants. The tobacco-made
PA was biologically active as was demonstrated through its abil-
ity to lyse a macrophage cell line in vitro when combined with LF
[11]. Also, mice immunized with the tomato-expressed PA gener-
ated lethal toxin neutralizing antibodies [3]. For the production of
an edible anthrax vaccine, Kim et al. [12] generated potato plants
expressing detectable amount of cholera toxin B-subunit – anthrax
LF conjugate fusion protein [12]. In an effort to produce an anthrax
vaccine in large quantities, PA was expressed in transgenic tobacco
chloroplasts [13,14]. It has been calculated that one acre of chloro-
plast transgenic plants could produce up to 360 million doses of
anthrax vaccine antigens [14]. Subcutaneous immunization ofmice
with partially purified chloroplast-derived or B. anthracis-derived
PAwith adjuvant yielded immunoglobulin G titers up to 1:320,000,
and both groups of mice survived challenge with lethal doses of
toxin. In a separate study, Chichester et al. [15] described a can-
didate subunit vaccine against B. anthracis consisting of domain 4
of PA (PAD4) and domain 1 of LF (LFD1). Each domain was fused
to lichenase, a thermostable enzyme from Clostridium thermocel-
lum, and transiently expressed in Nicotiana benthamiana using the
“launch vector” technology that combines elements of plant virus
RNA vectors and Agrobacterium binary plasmid [10]. Immunization
of mice with this candidate vaccine resulted in high titers of lethal
toxin neutralizing antibodies.
3.2. Plague
Y. pestis is the causative agent of plague that canoccur in bubonic
orpneumonic forms.Bacteria areusuallypassed tohumans through
the bite of a flea or by direct contact with, or inhalation of, infec-
tive materials. Y. pestis appears to be a good candidate agent for a
bioterrorist attack, because of the rapid spread of the disease from
person to person as a consequence of the use of an aerosolized
form of this agent [1,16]. Currently, there is no safe and effective
vaccine against plague. Two Y. pestis antigens are of interest for
developing new vaccines against plague: the anti-phagocytic cap-
sular envelope glycoprotein (F1) and the low calcium response
virulent antigen (V). In one study, the antigens F1, V, and the
fusion protein F1–V were produced by transient expression in N.
benthamiana using a deconstructed tobacco mosaic virus-based
system. All the plant-derived antigens, administered s.c. to guinea
pigs, elicited antigen-specific serum IgG titers and provided protec-
tion against an aerosol challenge of virulent Y. pestis [17]. Using a
similar transient system, Mett et al. [18] expressed the antigens F1
andVas fusionswith lichenase.When administered to Cynomolgus
Macaques, the purified plant-produced antigens stimulated strong
immune responses andprovided complete protection against lethal
challenge with Y. pestis [18]. In a separate study, the F1–V antigen
fusion protein was expressed in transgenic tomato plants for the
development of an alternative oral subunit vaccine against plague.
The immunogenicity of the plant-made vaccine was tested in mice
that were primed subcutaneously using bacterially produced F1–V
and boosted orallywith freeze-dried F1–V transgenic tomato fruits.
The vaccine elicited IgG1 in serum and mucosal IgA in fecal pellets
[16]. In a different study, the fusion protein F1–V was expressed in
transgenic tobacco chloroplasts. Themaximumexpression levels of
the fusion protein were observed in mature leaves and was as high
as 14.8% TSP [7].
3.3. Smallpox
Variola virus, which belongs to the family of Poxviridae, genus
othopoxvirus, is the causative agent of smallpox. The aerosol infec-
tivity, high mortality and stability of the variola virus make it a
potential and dangerous threat in biological warfare. In addition,
animal poxviruses such as monkeypox, and recombinant variants
of the variola virus, could be developed as biological weapons [1].
The existing smallpox vaccine, i.e. scarification with vaccinia virus
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Fig. 1. Stable nuclear expression of VACV proteins in tobacco plants. A sequence
encoding the FLAG epitopewas added at the C-terminus of theA27L andA33R coding
sequences. Theconstructswere cloned inbinaryvectors forAgrobacterium-mediated
transformation. (A) Efficiency of transformation (no. of transgenic shoots/100 co-
cultivated explants) with the binary vectors containing either A27L or A33R, and
efficiency of co-transformation with the two binary vectors. (B) Co-expression
of A33R and A27L recombinant polypeptides in three independent transgenic
tobacco plants (1–3). Total protein extracts from leaves were analyzed by SDS-PAGE
and protein blot using anti-FLAG antiserum. WT, protein extracts from wild-type
plants.
(VACV), is extremely effective but has a high reactogenicity with
adverse cardiac events and a wide range of contraindications [19].
Vaccine stockpiles are also low, since smallpox vaccine production
ceased in 1980. Good molecular candidates for the development
of a smallpox vaccine are the A27L and L1R proteins, specific to
the intracellular mature virus (IMV), and the A33R and B5R pro-
teins, specific to the extracellular enveloped virus (EEV). In our
laboratories, we are investigating the possibility to produce the
above-mentioned four immunogenic proteins of VACV in tobacco.
We first performed transient expression of A27L, A33R, L1R and
B5R in tobacco protoplasts and verified protein synthesis and sta-
bility in pulse-chase experiments. A33R and A27L proteins were
synthesized at much higher levels than the others, A27L being
also more stable than A33R [20]. Having verified the suitability
for plant expression, we stably expressed the A27L and the A33R
protein by Agrobacterium-mediated transformation of the nuclear
genome and biolistic transformation of the plastome. The inte-
gration of the A27L gene into the chloroplast genome resulted in
high-yield accumulation of the recombinant protein (Rigano et
al., unpublished, Table 1). In addition, since optimal protection
to the challenge is provided by a multicomponent smallpox vac-
cine [21], Agrobacterium-mediated co-transformation experiments
with the A33R and A27L genes are under way. Preliminary results
showed high frequency of co-transformation and co-expression of
the two proteins (Fig. 1) (Rigano et al., unpublished). In planta pro-
duction of the recombinant vaccinia virus B5 antigenic domain
(B5) was reported by Golovkin et al. [22]. The antigen was pro-
duced in soluble and insoluble forms upon transient and stable
plant transformation. Intranasal administration of soluble B5 led
to a rise of B5-specific immunoglobulins. Mice immunized i.m.
with B5 generated an antibody response that conferred protection
from challenge with a lethal dose of vaccinia virus [22]. The same
authors analyzed the impact of purity of plant-based B5 subunit
vaccine preparation on specific antibody responses in mice, and
demonstrated the efficiency of mucosal administration of plant-
derived smallpox vaccine in obtaining a potent immune response
[23].
4. Conclusion
The potential use of orthopoxvirus (OPV) in bioterrorism, the
occurrence of zoonotic OPV and SARS outbreaks, and the deliberate
release of B. anthracis in the United States in 2002, highlighted the
importance of the development of new generation vaccines against
bio-security-related organisms. The use of plants as bioreactors
for manufacturing high-volume reserves of subunit vaccines is an
economical and safe alternative to the facilities required for yeast,
Escherichia coli, andmammalian cells [16]. During the last decade, a
substantial amount of data has been accumulated on the immuno-
genity and safety of plant-made vaccines. Moreover, there have
been significant advances in improving the yield achieved formany
plant-derived antigens. However, several challenges remain to be
met in terms of social acceptability of plant-produced vaccines,
establishing regulatory guidelines for plant-produced materials
and improving the quality of the resulting products. Future studies
will also likely focus on the need to fully separate recombi-
nant antigens from potentially harmful secondary metabolites [4].
Downstreampurification costswill also need to be reduced, to fully
exploit the advantages associated with the use of transgenic plants
as bioreactors [24]. However, the growingnumber of antigens being
expressed in plant systems and the six plant-produced vaccine can-
didates evaluated in Phase I human clinical trials [10] are moving
us closer to the production of safe plant-made vaccines against
emerging infectious diseases or bioterrorism agents.
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